TITLE

How much has PCV reduced radiographic pneumonia?

AUTHOR(S)
Burke, Michael G.
PUB. DATE
March 2009
SOURCE
Contemporary Pediatrics;Mar2009, Vol. 26 Issue 3, p42
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses research on the use of pneumococcal conjugate vaccine (PCV) to lessen incidence of radiographic pneumonia. It references a study by M. S. Rutman et al, published in a 2009 issue of "Pediatric Emergency Care." According to the study involving 889 young highly febrile children with leukocytosis, only 18 percent of those given PCV developed radiologic pneumonia.
ACCESSION #
37152737

 

Related Articles

  • New PCV7 recommendations.  // Infectious Diseases in Children;May2008, Vol. 21 Issue 5, p13 

    The article reports on the updated recommendations for the use of the 7-valent pneumococcal conjugate vaccine in children aged 24 to 59 months. The Pneumococcal Vaccines Work Group presented data regarding the safety and immunogenicity of PCV7 among children in this age group at the Advisory...

  • Update on Pneumococcal Conjugate Vaccine Shortage. Morantz, Carrie; Torrey, Brian // American Family Physician;9/1/2004, Vol. 70 Issue 5, p985 

    Presents an update on pneumococcal conjugate vaccine shortage in the U.S., as of September 2004. Cause of the shortage; Recommendations given to physicians concerning the vaccination of children; Advantage of catch-up vaccination.

  • Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection. Jackson, Lisa A.; Janoff, Edward N. // Clinical Infectious Diseases;11/15/2008, Vol. 47 Issue 10, p1328 

    Pneumococcal polysaccharide vaccine has been licensed for use in the United States for >30 years, and two-thirds of the elderly population in the United States have received this vaccine. Observational studies have demonstrated that pneumococcal polysaccharide vaccine reduces the risk of...

  • Infants too young to receive pneumococcal conjugate vaccine benefit from herd immunity. Carter, R. J. F. // Thorax;Jul2006, Vol. 61 Issue 7, p610 

    The article reports that infants too young to receive a heptavalent pneumococcal conjugate vaccine (PCV7) are benefiting from herd immunity. Evidence has shown that the rate of invasive pneumococcal disease (IPD) among children younger than 2 years has reduced since the introduction of PCV7....

  • Invasive Pneumococcal Infections in Canadian Children, 1991-1998: Implications for New... Scheifele, David; Halperin, Scott; Pelletier, Louise; Talbot, James // Clinical Infectious Diseases;7/1/2000, Vol. 31 Issue 1, p58 

    Presents the results of a nationwide epidemiological study of invasive pneumococcal infections in Canadian children from 1991 to 1998. Effects of vaccination on colonization rates with vaccine serotypes; Age distribution of invasive infections; Factors to consider in establishing vaccination...

  • Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study. Jokinen, Jukka; Rinta-Kokko, Hanna; Siira, Lotta; Palmu, Arto A.; Virtanen, Mikko J.; Nohynek, Hanna; Virolainen-Julkunen, Anni; Toropainen, Maija; Nuorti, J. Pekka // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Background: The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Program (NVP) in September 2010 with a 2+1 schedule (3, 5, 12 months) without catch-up vaccinations. We evaluated the direct and indirect effects of PCV10 on invasive...

  • Incidence of Pneumococcal Disease Due to Non-Pneumococcal Conjugate Vaccine (PCV7) Serotypes in the United States during the Era of Widespread PCV7 Vaccination, 1998-2004. Hicks, Lauri A.; Harrison, Lee H.; Flannery, Brendan; Hadler, James L.; Schaffner, William; Craig, Allen S.; Jackson, Delois; Thomas, Ann; Beall, Bernard; Lynfield, Ruth; Reingold, Arthur; Farley, Monica M.; Whitney, Cynthia G. // Journal of Infectious Diseases;11/1/2007, Vol. 196 Issue 9, p1346 

    Background. Widespread use of pneumococcal conjugate vaccine (PCV7) resulted in decreases in invasive disease among children and elderly persons. The benefits may be offset by increases in disease due to serotypes not included in the vaccine (hereafter, ‘nonvaccine serotypes’). We...

  • Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine Administered According to 4 Different Primary Immunization Schedules in Infants. Spijkerman, Judith; Veenhoven, Reinier H.; Wijmenga-Monsuur, Alienke J.; Elberse, Karin E. M.; van Gageldonk, Pieter G. M.; Knol, Miriam J.; de Melker, Hester E.; Sanders, Elisabeth A. M.; Schouls, Leo M.; Berbers, Guy A. M. // JAMA: Journal of the American Medical Association;9/4/2013, Vol. 310 Issue 9, p930 

    IMPORTANCE Immunization schedules with pneumococcal conjugate vaccine (PCV) differ among countries regarding the number of doses, age at vaccinations, and interval between doses. OBJECTIVE To assess the optimal primary vaccination schedule by comparing immunogenicity of 13-valent PCV (PCV13) in...

  • UK rise in pneumococcal strain after jab.  // GP: General Practitioner;4/18/2008, p3 

    The article reports on the occurrence of potential cases of pneumonia in children in Great Britain even if they have received a pneumococcal vaccine. Researchers found an increase of pneumococcal bacteria serotype that is not covered by the current vaccine. The number of cases of the strain in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics